Literature DB >> 19075053

Selectivity of TMC207 towards mycobacterial ATP synthase compared with that towards the eukaryotic homologue.

Anna C Haagsma1, Rooda Abdillahi-Ibrahim, Marijke J Wagner, Klaas Krab, Karen Vergauwen, Jerome Guillemont, Koen Andries, Holger Lill, Anil Koul, Dirk Bald.   

Abstract

The diarylquinoline TMC207 kills Mycobacterium tuberculosis by specifically inhibiting ATP synthase. We show here that human mitochondrial ATP synthase (50% inhibitory concentration [IC(50)] of >200 microM) displayed more than 20,000-fold lower sensitivity for TMC207 compared to that of mycobacterial ATP synthase (IC(50) of 10 nM). Also, oxygen consumption in mouse liver and bovine heart mitochondria showed very low sensitivity for TMC207. These results suggest that TMC207 may not elicit ATP synthesis-related toxicity in mammalian cells. ATP synthase, although highly conserved between prokaryotes and eukaryotes, may still qualify as an attractive antibiotic target.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19075053      PMCID: PMC2650532          DOI: 10.1128/AAC.01393-08

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  21 in total

1.  14-3-3 protein is a regulator of the mitochondrial and chloroplast ATP synthase.

Authors:  T D Bunney; H S van Walraven; A H de Boer
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-13       Impact factor: 11.205

2.  Mitochondrial ATP synthase levels in brown adipose tissue are governed by the c-Fo subunit P1 isoform.

Authors:  Tatiana V Kramarova; Irina G Shabalina; Ulf Andersson; Rolf Westerberg; Inger Carlberg; Josef Houstek; Jan Nedergaard; Barbara Cannon
Journal:  FASEB J       Date:  2007-07-31       Impact factor: 5.191

3.  In vitro antimycobacterial spectrum of a diarylquinoline ATP synthase inhibitor.

Authors:  Emma Huitric; Peter Verhasselt; Koen Andries; Sven E Hoffner
Journal:  Antimicrob Agents Chemother       Date:  2007-08-20       Impact factor: 5.191

4.  The protonmotive force is required for maintaining ATP homeostasis and viability of hypoxic, nonreplicating Mycobacterium tuberculosis.

Authors:  Srinivasa P S Rao; Sylvie Alonso; Lucinda Rand; Thomas Dick; Kevin Pethe
Journal:  Proc Natl Acad Sci U S A       Date:  2008-08-12       Impact factor: 11.205

Review 5.  Unique rotary ATP synthase and its biological diversity.

Authors:  Christoph von Ballmoos; Gregory M Cook; Peter Dimroth
Journal:  Annu Rev Biophys       Date:  2008       Impact factor: 12.981

6.  Multiple effects of 2,2',5,5'-tetrachlorobiphenyl on oxidative phosphorylation in rat liver mitochondria.

Authors:  Vida Mildaziene; Zita Nauciene; Rasa Baniene; Jurgita Grigiene
Journal:  Toxicol Sci       Date:  2002-02       Impact factor: 4.849

7.  A computational model of the inhibition of Mycobacterium tuberculosis ATPase by a new drug candidate R207910.

Authors:  Marc R de Jonge; Luc H M Koymans; Jérôme E G Guillemont; Anil Koul; Koen Andries
Journal:  Proteins       Date:  2007-06-01

8.  Structure, functioning, and assembly of the ATP synthase in cells from patients with the T8993G mitochondrial DNA mutation. Comparison with the enzyme in Rho(0) cells completely lacking mtdna.

Authors:  J J García; I Ogilvie; B H Robinson; R A Capaldi
Journal:  J Biol Chem       Date:  2000-04-14       Impact factor: 5.157

9.  Diarylquinolines target subunit c of mycobacterial ATP synthase.

Authors:  Anil Koul; Najoua Dendouga; Karen Vergauwen; Brenda Molenberghs; Luc Vranckx; Rudy Willebrords; Zorica Ristic; Holger Lill; Ismet Dorange; Jerome Guillemont; Dirk Bald; Koen Andries
Journal:  Nat Chem Biol       Date:  2007-05-13       Impact factor: 15.040

10.  Diarylquinolines are bactericidal for dormant mycobacteria as a result of disturbed ATP homeostasis.

Authors:  Anil Koul; Luc Vranckx; Najoua Dendouga; Wendy Balemans; Ilse Van den Wyngaert; Karen Vergauwen; Hinrich W H Göhlmann; Rudy Willebrords; Alain Poncelet; Jerome Guillemont; Dirk Bald; Koen Andries
Journal:  J Biol Chem       Date:  2008-07-14       Impact factor: 5.157

View more
  60 in total

Review 1.  The chemical biology of new drugs in the development for tuberculosis.

Authors:  Clifton E Barry; John S Blanchard
Journal:  Curr Opin Chem Biol       Date:  2010-05-07       Impact factor: 8.822

Review 2.  TMC207: the first compound of a new class of potent anti-tuberculosis drugs.

Authors:  Alberto Matteelli; Anna Cc Carvalho; Kelly E Dooley; Afranio Kritski
Journal:  Future Microbiol       Date:  2010-06       Impact factor: 3.165

Review 3.  The c-Ring of the F1FO-ATP Synthase: Facts and Perspectives.

Authors:  Salvatore Nesci; Fabiana Trombetti; Vittoria Ventrella; Alessandra Pagliarani
Journal:  J Membr Biol       Date:  2015-11-30       Impact factor: 1.843

4.  First use of bedaquiline in a patient with XDR-TB in Singapore.

Authors:  Angeline Poh-Gek Chua; Grace Si-Ru Hoo; Cynthia Bin-Eng Chee; Yee Tang Wang
Journal:  BMJ Case Rep       Date:  2015-09-23

5.  Pyrazinoic acid decreases the proton motive force, respiratory ATP synthesis activity, and cellular ATP levels.

Authors:  Ping Lu; Anna C Haagsma; Hoang Pham; Janneke J Maaskant; Selena Mol; Holger Lill; Dirk Bald
Journal:  Antimicrob Agents Chemother       Date:  2011-08-29       Impact factor: 5.191

Review 6.  Bedaquiline - The first ATP synthase inhibitor against multi drug resistant tuberculosis.

Authors:  Mageshwaran Lakshmanan; Alphienes Stanley Xavier
Journal:  J Young Pharm       Date:  2013-12-30

Review 7.  Tuberculosis Drug Development: History and Evolution of the Mechanism-Based Paradigm.

Authors:  Sumit Chakraborty; Kyu Y Rhee
Journal:  Cold Spring Harb Perspect Med       Date:  2015-04-15       Impact factor: 6.915

8.  Bedaquiline.

Authors:  Sebastiaan C Goulooze; Adam F Cohen; Robert Rissmann
Journal:  Br J Clin Pharmacol       Date:  2015-07-02       Impact factor: 4.335

9.  Turbine enzyme's structure in the crosshairs to target tuberculosis.

Authors:  Thomas M Duncan
Journal:  Proc Natl Acad Sci U S A       Date:  2019-02-19       Impact factor: 11.205

10.  The antibiotic bedaquiline activates host macrophage innate immune resistance to bacterial infection.

Authors:  Juan Manuel Coya; Alexandra Maure; Anne Biton; Roland Brosch; Brigitte Gicquel; Alexandre Giraud-Gatineau; Michael Thomson; Elliott M Bernard; Jade Marrec; Maximiliano G Gutierrez; Gérald Larrouy-Maumus; Ludovic Tailleux
Journal:  Elife       Date:  2020-05-04       Impact factor: 8.140

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.